PeptideDB

LCMV GP (61-80)

CAS: 232598-19-5 F: C108H160N24O31 W: 2290.60

LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corr
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corresponds to amino acids 61-80. LCMV GP (61-80) is a specific epitope which can induce CD4+ T-cell response[1][2][3].
Name LCMV GP (61-80)
CAS 232598-19-5
Sequence Gly-Leu-Lys-Gly-Pro-Asp-Ile-Tyr-Lys-Gly-Val-Tyr-Gln-Phe-Lys-Ser-Val-Glu-Phe-Asp
Shortening GLKGPDIYKGVYQFKSVEFD
Formula C108H160N24O31
Molar Mass 2290.60
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Reference [1]. Rodriguez F, et, al. CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol. 2001 Nov; 75(21): 10421-30. [2]. Andargachew R, et, al. CD4 T Cell Affinity Diversity Is Equally Maintained during Acute and Chronic Infection. J Immunol. 2018 Jul 1; 201(1):19-30. [3]. Homann D, et, al. Mapping and restriction of a dominant viral CD4+ T cell core epitope by both MHC class I and MHC class II. Virology. 2007 Jun 20; 363(1): 113-23.